Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Jyong Biotech Presents Botreso at BIO 2026
Business convention participation

Jyong Biotech Presents Botreso at BIO 2026

Analysis based on 6 articles · First reported Jul 02, 2026 · Last updated Jul 03, 2026

Sentiment
40
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The participation of Jyong Biotech in BIO 2026 and its efforts to advance global licensing discussions for Botreso could positively impact its stock price by signaling potential future revenue streams and market expansion. Increased visibility and potential partnerships could lead to greater investor confidence in Jyong Biotech.

Biotechnology Pharmaceuticals
Event Summary

Jyong Biotech participated in the BIO International Convention (BIO 2026) in San Diego, California, from June 22 to June 25, 2026. During the convention, Jyong Biotech presented its botanical new drug candidate, Botreso (API-1), which targets benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The company has conducted four Phase III clinical trials for Botreso across the United States and Taiwan and is accelerating its New Drug Application (NDA) preparations and global licensing plans. Jyong Biotech aims to expedite commercialization in key markets, including the United States, Europe, and Asia, through regional licensing and strategic alliances. Ms. Fu-Feng Kuo, Chairwoman of Jyong Biotech, highlighted the event as an important step for entering the global market and advancing plant-derived therapeutics.

Key Actions
90 Jyong Biotech participated in convention BIO International Convention
80 Jyong Biotech accelerating preparations
75 Jyong Biotech presented drug candidate
Entities Involved
priv
Jyong Biotech
Jyong Biotech participated in BIO 2026 to present its drug candidate Botreso and engage in global licensing discussions, aiming to expand its market presence and commercialization efforts.
Importance 100.0 Sentiment 50.0
oth
BIO International Convention
The BIO International Convention served as a platform for Jyong Biotech to showcase its botanical drug portfolio and connect with global pharmaceutical companies and investors.
Importance 70.0 Sentiment 0.0
per
Fu-Feng Kuo
Ms. Fu-Feng Kuo, Chairwoman of Jyong Biotech, emphasized the importance of BIO 2026 for entering the global market and advancing plant-derived therapeutics.
Importance 60.0 Sentiment 0.0
loc
Asia
Asia is one of the key markets where Jyong Biotech aims to commercialize Botreso through regional licensing and strategic alliances.
Importance 20.0 Sentiment 0.0
cnt
Taiwan
Taiwan is the headquarters of Jyong Biotech and one of the locations where Phase III clinical trials for Botreso were conducted.
Importance 20.0 Sentiment 0.0
cnt
United States
The United States is one of the key markets where Jyong Biotech aims to commercialize Botreso through regional licensing and strategic alliances.
Importance 20.0 Sentiment 0.0
loc
Europe
Europe is one of the key markets where Jyong Biotech aims to commercialize Botreso through regional licensing and strategic alliances.
Importance 20.0 Sentiment 0.0
Relationships
Taiwan security partner ↔ United States Taiwan relies heavily on the United States for defensive weaponry and security support against Chinese territorial claim
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.